VVOS
Vivos Therapeutics, Inc.
VVOS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
VVOS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VVOS's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
VVOS PE Valuation
VVOS has no meaningful PE right now: it lost money over the past year.
VVOS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect VVOS's losses to grow, with revenue growing.
VVOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$10.12 | +$2.88 |
| Q2 2024 | -$11.47 | +$6.28 |
| Q1 2024 | -$15.37 | +$6.13 |
| Q4 2023 | -$15.49 | +$10.51 |
| Q3 2023 | -$13.00 | +$16.00 |
| Q2 2023 | -$17.75 | +$11.25 |
| Q1 2023 | -$21.50 | +$4.00 |
| Q4 2022 | -$26.00 | -$2.00 |
VVOS is still losing money, but far less than before: $1.90 per share over the past year, against $29.00 at its worst in mid-2022.
VVOS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.2M | +35% |
| Q1 2026 | $5.1M | +70% |
| Q4 2025 | $3.8M | +3.4% |
| Q3 2025 | $6.8M | +76% |
| Q2 2025 | $3.8M | -5.8% |
| Q1 2025 | $3M | -12% |
| Q4 2024 | $3.7M | +14% |
| Q3 2024 | $3.9M | +17% |
VVOS's revenue has grown year over year for four quarters in a row: $5M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | +34 points |
| Q1 2026 | -129% | +1.2 points |
| Q4 2025 | -167% | -91 points |
| Q3 2025 | -70% | -1.3 points |
| Q2 2025 | -127% | -80 points |
| Q1 2025 | -130% | -19 points |
| Q4 2024 | -76% | +56 points |
| Q3 2024 | -69% | +37 points |
VVOS's operating margin was −94% last quarter, up 34 points from the same quarter a year ago.
VVOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.6M | +$701K |
| Q1 2026 | -$6M | -$2.1M |
| Q4 2025 | -$5.3M | -$2.2M |
| Q3 2025 | -$4.1M | +$301K |
| Q2 2025 | -$4.3M | -$1.2M |
| Q1 2025 | -$3.9M | -$1.3M |
| Q4 2024 | -$3.1M | -$192K |
| Q3 2024 | -$4.4M | -$1.4M |
VVOS has burned cash in almost every quarter: −$19M over the past year, against −$16M the year before.
VVOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +3M shares |
| 1 year | +106% | +9.1M shares |
| 3 years | +1982% | +16.8M shares |
| 5 years | +3457% | +17.2M shares |
VVOS has 18M diluted shares, up 106% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2M |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $150,000 |
| Q4 2019 | — |
| Q3 2019 | $50,000 |
VVOS Net Leverage
VVOS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VVOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.8 | Oversold |
| Stochastic | 1.3 | Oversold |
VVOS's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
VVOS PE vs Healthcare Sector
VVOS has no meaningful PE right now: it lost money over the past year.
VVOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.13 | 23% below |
| 20 week MA | $0.24 | 58% below |
| 50 week MA | $0.88 | 89% below |
| 100 week MA | $2.22 | 95% below |
| 200 week MA | $4.63 | 98% below |
VVOS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
VVOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $224.8 | $184.5 | -18% |
| 2021 | $184.5 | $68.5 | -63% |
| 2022 | $68.5 | $11.9 | -83% |
| 2023 | $11.9 | $12.4 | +4.3% |
| 2024 | $12.4 | $4.65 | -63% |
| 2025 | $4.65 | $2.03 | -56% |
| 2026 YTD | $2.03 | $0.10 | -95% |
VVOS has finished lower in five of the last six years. It's down 95% so far in 2026.